Bespak maintains improved performance:
This article was originally published in Clinica
Executive Summary
Strong demand for its asthma inhaler valves drove first-half sales and profit increases at Bespak, the UK-based drug delivery device manufacturer. Sales rose by 10.4% to £39.4 million ($67 million) in the six months to November 1st, 1996. Pre-tax profit for the half year was 42.9% ahead of year-earlier figures, at £5 million. Bespak, which returned to profitability in fiscal 1996, is forecasting continued progress through the second half-year. The company expects further growth in UK sales of drug delivery devices, and anticipates improved profitability for its US operations.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.